Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma [0.03%]
GPC3靶向TCR融合构建体CT0180治疗晚期肝细胞癌的I期临床试验
Xuqi Sun,Wanwan Gao,Chunhui Shou et al.
Xuqi Sun et al.
Purpose: Treatment options for advanced hepatocellular carcinoma (HCC) remain limited, and responses to later-line therapies are modest. Glypican-3 (GPC3), highly expressed in HCC but rarely in normal tissues, is an attra...
Microsatellite Instability Identifies a Rare but Clinically Relevant Subset of Sarcomas: Insights from the Largest Clinically Sequenced Cohort with Therapeutic Implications [0.03%]
微卫星不稳定性确定了肉瘤中一个罕见但临床上重要的亚型：来自最大临床测序队列的治疗启示
Carla Saoud,Chad Vanderbilt,Jamal Benhamida et al.
Carla Saoud et al.
Introduction: Microsatellite instability (MSI) has broad biologic and clinical relevance across solid tumors, yet its role in sarcomas remains poorly defined. We delineate the clinicopathologic, molecular, and treatment-r...
Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial [0.03%]
在乳腺癌SweBCG91RT随机临床试验中调查前列腺癌放射反应签名
Shuang G Zhao,Erik Holmberg,Dan Lundstedt et al.
Shuang G Zhao et al.
Purpose: PORTOS is a 24-gene radiation response signature developed and validated in multiple randomized trials in prostate cancer. Given its basis in general radiation and DNA damage response pathways, we sought to evalu...
Feasibility and activity of concurrent neoadjuvant chemotherapy and radiation therapy in patients with high-risk soft tissue sarcoma [0.03%]
高危软组织肉瘤患者同期新辅助化疗和放疗的可行性和活性
Elena Palassini,Sara Pizzamiglio,Emanuela Palmerini et al.
Elena Palassini et al.
Objective: The ISG-STS 1001 was an international, randomized, phase III, trial for localized, high-risk, STS comparing neoadjuvant ChT with epirubicin and ifosfamide (EI) versus a histology-tailored regimen. The trial inc...
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study [0.03%]
用于HRD阳性晚期卵巢癌新辅助治疗的奥拉帕利联合派姆单抗疗法：一项初步研究
Kenichi Harano,Takehiro Nakao,Shin Nishio et al.
Kenichi Harano et al.
Purpose: Preclinical studies suggest that poly(ADP-ribose) polymerase (PARP) inhibition enhances tumor immunogenicity through STING pathway activation, providing rationale for combination with immune checkpoint inhibitors...
Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer [0.03%]
转录标志指示RB功能与子宫内膜癌对CDK4/6抑制的反应相关性
Zelei Yang,Upendra Raj Bhattarai,Martin K Hayes et al.
Zelei Yang et al.
Purpose: CDK4/6 inhibitors (CDK4/6is) are being investigated in endometrial cancer (EC) clinical trials with some patients showing a significant response. However, there are few biomarkers to predict which EC patients wil...
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal? [0.03%]
从细胞凋亡恢复药物Xevinapant的视角看“SMAC”下调：它的故事揭示了什么？
Pablo Jimenez-Labaig,Oriol Mirallas,Charleen Chan Wah Hak et al.
Pablo Jimenez-Labaig et al.
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAPs) from the SMAC-mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and pr...
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388) [0.03%]
曲普替尼联合[177Lu]镥-多妥泰治疗神经内分泌肿瘤患者的I期多中心研究（ETCTN 10388）
Aman Chauhan,Heidi L Weiss,Charles Kunos et al.
Aman Chauhan et al.
Introduction: Next generation of Theranostics studies are looking at novel combinations with radiation sensitizers to enhance PRRT's efficacy. Here, we present safety and efficacy data from a multi-center phase 1 study of...
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer [0.03%]
非小细胞肺癌患者中CDKN2A/MTAP缺失的基因组景观及其与治疗结果的相关性
Natalie I Vokes,Jessica L Symons,Brooke Rhead et al.
Natalie I Vokes et al.
Introduction: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NS...
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial [0.03%]
耐昔妥珠单抗联合派姆单抗治疗≥50%PD-L1表达的晚期非小细胞肺癌患者疗效和安全性：一项非随机Ⅱ期临床试验
Atsushi Horiike,Hiroshi Wakui,Shunichi Sugawara et al.
Atsushi Horiike et al.
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1)...